Inclusion Criteria

Concurrent Medication:

Allowed:

• Recommended:
• Standard immunizations. Should repeat MMR 3 months after discontinuing study.
• Benadryl and/or aspirin.
• Pneumocystis carinii pneumonia prophylaxis.
• Systemic ketoconazole and acyclovir, or oral nystatin for acute therapy.
• Aerosol ribavirin for short-term treatment of RSV.

Concurrent Treatment:

Allowed:

• Blood transfusion.

Patients must have the following:

• Parent or guardian available to give written informed consent.
• Protocol requires prior Institutional Review Board (IRB) approval before any subject is entered into study.

Prior Medication:

Allowed:

• Gammaglobulin, intravenous (IV) or intramuscular (IM).
• Immunoglobulin, IV (IVIG).
• Maternal antiretroviral treatment during pregnancy.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

• Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.
• Presence of serious acute infection requiring parenteral treatment at time of study entry.

Concurrent Medication:

Excluded:

• Prophylaxis for oral candidiasis or otitis media or other infections.
• Immunoglobulin therapy (except single dose or for hypogammaglobulinemia).
• Ketoconazole, acyclovir, or nystatin for prophylaxis.

Patients with the following are excluded:

• Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.
• Presence of serious acute infection requiring parenteral treatment at time of study entry.

Prior Medication:

Excluded:

• Antiretroviral treatment or experimental treatment within 2 weeks of entry.